IONIS PHARMACEUTICALS INC (IONS) — SEC Financial Statements & Analysis

IONIS PHARMACEUTICALS INC (IONS) is a pharmaceutical preparations company, incorporated in CA. IONIS PHARMACEUTICALS INC trades on Nasdaq as: IONS. IONIS PHARMACEUTICALS INC (IONS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29. Based on that filing, IONIS PHARMACEUTICALS INC carries a market cap of $13.12B, a P/E ratio of -23.21x, a P/B ratio of 29.83x, a P/S ratio of 15.01x, an enterprise value of $12.77B, and an EV/EBITDA multiple of -21.93x. On profitability, it posts a gross margin of 98.17%, an operating margin of -68.00%, a net margin of -64.66%, a Return on Equity (ROE) of -105.50%, a Return on Assets (ROA) of -18.90%, and a Return on Invested Capital (ROIC) of -109.00%. Per share, it reports EPS of $-3.42, diluted EPS of $-3.42, free cash flow per share of $-3.39, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -7.41% year-over-year, net income growth of 110.72% year-over-year, and EPS growth of 102.71% year-over-year. On the balance sheet, it maintains a current ratio of 7.89x, a quick ratio of 7.73x, working capital of $2.18B, a debt-to-equity ratio of 5.81x, a debt ratio of 0.85, an interest coverage ratio of -31.58x, free cash flow of $-560.84M (TTM), and net debt of $-350.06M. Figures sourced from SEC EDGAR.

Market Cap

$13.12B

P/E TTM

-23.21x

EPS TTM

$-3.42

P/B TTM

29.83x

ROE TTM

-105.50%

ROA TTM

-18.90%

Debt To Equity

5.81x

Free Cash Flow TTM

$-560.84M

Net Revenue TTM Growth 1Y

-7.41%

Data as of 2026-06-30 · Source: SEC EDGAR